Klotho Neurosciences Inc (KLTO)

$0.36 0.00 (-0.19%)
Market Cap 26.45M
Revenue (ttm) 0.00
Net Income (ttm) -6.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 418,300
Avg Vol 820,160
Day's Range N/A - N/A
Shares Out 72.54M
Stochastic %K 16%
Beta 10.05
Analysts Strong Buy
Price Target N/A

Company Profile

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha,...

Industry: Biotechnology
Sector: Healthcare
Phone: 833 931 6330
Address:
13576 Walnut Street, Suite A, Omaha, United States
Tycoon_Trader
Tycoon_Trader Dec. 23 at 2:45 PM
$KLTO $KLTO – Dilution + Delisting Risk 🚨 • Price sliding hard, now around $0.36. • Company issued Series C Preferreds → convertible into tens of millions of common shares = massive dilution ahead. • Nasdaq already flagged KLTO for delisting risk due to compliance failures. • Delayed filings = weak transparency = fading investor trust. • Micro‑cap biotech = volatility playground. Expect pump & dump cycles until fundamentals show up. ⚠️ Bottom line: KLTO is in a death spiral unless management fixes compliance + stops dilution. Traders beware—this is textbook dilution pressure. 👉 Not financial advice. Just sharing my perspective for education + discussion.
0 · Reply
Beanie_Mojo
Beanie_Mojo Dec. 22 at 8:07 PM
$KLTO
0 · Reply
playtrades2day
playtrades2day Dec. 21 at 9:08 PM
$KLTO January 8, 2026: CEO Dr. Joseph Sinkule is expected to be in San Francisco for the Biotech Showcase.
0 · Reply
MikiTrader
MikiTrader Dec. 21 at 4:12 AM
$KLTO Animal results are so strong that using it in humans is actually scary. There have never been proper human trials. Klotho is one of the biggest “ifs” in biotech history.
0 · Reply
Beanie_Mojo
Beanie_Mojo Dec. 20 at 3:06 PM
$KLTO
0 · Reply
skagnetti13
skagnetti13 Dec. 19 at 6:16 PM
$KLTO Choke on it Stinkhole!
0 · Reply
zack_instock
zack_instock Dec. 17 at 4:37 PM
$KLTO ready for delist?
0 · Reply
Argesch
Argesch Dec. 17 at 8:56 AM
$KLTO 2026 folks, patience is the mother of science, take it easy teddy bears..
1 · Reply
Dontbadick
Dontbadick Dec. 16 at 5:38 AM
$KLTO lol pos
0 · Reply
skagnetti13
skagnetti13 Dec. 15 at 3:27 PM
$KLTO
0 · Reply
Latest News on KLTO
Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Nov 7, 2025, 10:03 AM EST - 6 weeks ago

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Oct 16, 2025, 8:00 AM EDT - 2 months ago

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Klotho Neurosciences Announces Expiration of Letter of Intent

Oct 7, 2025, 6:20 PM EDT - 2 months ago

Klotho Neurosciences Announces Expiration of Letter of Intent

Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership

Sep 30, 2025, 8:30 AM EDT - 3 months ago

Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

Sep 8, 2025, 8:00 AM EDT - 3 months ago

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

Aug 18, 2025, 8:30 AM EDT - 4 months ago

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

Aug 12, 2025, 6:00 AM EDT - 4 months ago

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Jul 25, 2025, 9:05 PM EDT - 5 months ago

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Jul 24, 2025, 1:30 PM EDT - 5 months ago

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

Jul 22, 2025, 10:21 AM EDT - 5 months ago

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

Jul 16, 2025, 6:00 AM EDT - 5 months ago

Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

Jul 10, 2025, 5:00 AM EDT - 5 months ago

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

This Penny Stock Exploded 500% In June: What You Need To Know

Jun 30, 2025, 11:07 AM EDT - 6 months ago

This Penny Stock Exploded 500% In June: What You Need To Know

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

Jun 30, 2025, 2:00 AM EDT - 6 months ago

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population

Jun 24, 2025, 5:00 AM EDT - 6 months ago

Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population

KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS

Jun 18, 2025, 7:00 AM EDT - 6 months ago

KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS

KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

Jun 16, 2025, 7:00 AM EDT - 6 months ago

KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?

Jun 10, 2025, 11:00 AM EDT - 7 months ago

Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?

KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")

Jun 9, 2025, 7:00 AM EDT - 7 months ago

KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Jan 8, 2025, 11:00 AM EST - 1 year ago

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein

Jun 26, 2024, 5:00 AM EDT - 1 year ago

ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein

Tycoon_Trader
Tycoon_Trader Dec. 23 at 2:45 PM
$KLTO $KLTO – Dilution + Delisting Risk 🚨 • Price sliding hard, now around $0.36. • Company issued Series C Preferreds → convertible into tens of millions of common shares = massive dilution ahead. • Nasdaq already flagged KLTO for delisting risk due to compliance failures. • Delayed filings = weak transparency = fading investor trust. • Micro‑cap biotech = volatility playground. Expect pump & dump cycles until fundamentals show up. ⚠️ Bottom line: KLTO is in a death spiral unless management fixes compliance + stops dilution. Traders beware—this is textbook dilution pressure. 👉 Not financial advice. Just sharing my perspective for education + discussion.
0 · Reply
Beanie_Mojo
Beanie_Mojo Dec. 22 at 8:07 PM
$KLTO
0 · Reply
playtrades2day
playtrades2day Dec. 21 at 9:08 PM
$KLTO January 8, 2026: CEO Dr. Joseph Sinkule is expected to be in San Francisco for the Biotech Showcase.
0 · Reply
MikiTrader
MikiTrader Dec. 21 at 4:12 AM
$KLTO Animal results are so strong that using it in humans is actually scary. There have never been proper human trials. Klotho is one of the biggest “ifs” in biotech history.
0 · Reply
Beanie_Mojo
Beanie_Mojo Dec. 20 at 3:06 PM
$KLTO
0 · Reply
skagnetti13
skagnetti13 Dec. 19 at 6:16 PM
$KLTO Choke on it Stinkhole!
0 · Reply
zack_instock
zack_instock Dec. 17 at 4:37 PM
$KLTO ready for delist?
0 · Reply
Argesch
Argesch Dec. 17 at 8:56 AM
$KLTO 2026 folks, patience is the mother of science, take it easy teddy bears..
1 · Reply
Dontbadick
Dontbadick Dec. 16 at 5:38 AM
$KLTO lol pos
0 · Reply
skagnetti13
skagnetti13 Dec. 15 at 3:27 PM
$KLTO
0 · Reply
Tycoon_Trader
Tycoon_Trader Dec. 15 at 3:01 PM
$KLTO Dr. Joseph A. Sinkule, CEO really knows how to reward his investors like no other CEO !
0 · Reply
zack_instock
zack_instock Dec. 13 at 2:37 PM
$KLTO Be legend, wouldn’t you? Legend of delist?
0 · Reply
Beanie_Mojo
Beanie_Mojo Dec. 12 at 1:24 PM
$KLTO This is a sad one . 😢
1 · Reply
CouchCushionCash
CouchCushionCash Dec. 12 at 3:39 AM
$KLTO burn it to the ground Sinkhole. you are the worst of the worst.
0 · Reply
Tycoon_Trader
Tycoon_Trader Dec. 11 at 7:06 PM
$KLTO We need Dr. Jeffrey Stein, Ph.D of CDTX to become the CEO of KLTO. This company has huge potential!
0 · Reply
mirkst
mirkst Dec. 11 at 10:15 AM
$KLTO They're gonna RS IMO by March 16 2016.
2 · Reply
Beanie_Mojo
Beanie_Mojo Dec. 10 at 9:01 PM
$KLTO 🚨
0 · Reply
Tycoon_Trader
Tycoon_Trader Dec. 9 at 4:52 PM
$KLTO KLTO: Compliance Clock Extended, But Risks Remain As of December 9, 2025, Klotho Neurosciences (KLTO) remains listed on Nasdaq, but only under conditional extension granted by the Nasdaq Hearings Panel. The company now has until March 26, 2026 to regain compliance with Nasdaq’s listing requirements.
0 · Reply
Beanie_Mojo
Beanie_Mojo Dec. 8 at 2:46 PM
$KLTO ......
0 · Reply
RockLesnar
RockLesnar Dec. 8 at 9:36 AM
$KLTO
0 · Reply
Mattzzzz
Mattzzzz Dec. 7 at 4:23 AM
$KLTO
0 · Reply
zack_instock
zack_instock Dec. 6 at 11:21 AM
$KLTO keep it up?
0 · Reply